GlassScriptPhysician profile
Galo Rodarte
NPI 1376585489
$4,458.23
in general payments reported to CMS, 2019-2025
26 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $386 · 2021: $689 · 2022: $819 · 2023: $590 · 2024: $238 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Debt Forgiveness: $57.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.84 |
| Debt Forgiveness | $57.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.19 | 2019-2025 | Synthroid, Ubrelvy |
| Lilly USA, LLC | $431.71 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $410.88 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $335.35 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $286.10 | 2019-2023 | Ozempic |
| Merck Sharp & Dohme LLC | $257.99 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $233.56 | 2019-2022 | |
| Insulet Corporation | $201.59 | 2021-2023 | Omnipod |
| Amgen INC. | $178.78 | 2019-2025 | Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.52 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $142.06 | 2019 | |
| Abbott Laboratories | $141.70 | 2021-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $130.74 | 2019-2024 | Korlym |
| Pfizer INC. | $126.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $125.06 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $123.09 | 2019-2023 | Livalo |
| Baxter Healthcare | $114.74 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $99.66 | 2019-2021 | |
| Dexcom, INC. | $75.90 | 2022-2023 | Dexcom G6 Transmitter |
| Welch Allyn | $57.37 | 2021 | |
| Arbor Pharmaceuticals, INC. | $51.22 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $27.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.46 | 2025 | |
| Tonix Medicines, INC. | $18.29 | 2025 | Tonmya |
| Radius Health, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Galo Rodarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.